-transparent.png){kind=logo}
Systemic or topical treatment with E-5-(2-bromovinyl)2'-deoxyuridine (BVDU) showed significant efficacy against orofacial infection with herpes simplex virus type 1 (HSV-1) in hairless mice. The chemotherapeutic response to BVDU was dose-dependent and clearly evident even when the treatment was initiated during the clinical manifestation of HSV-1 infection at 72 hr after inoculation. Early initiation of therapy with BVDU at 3 or 24 hr after inoculation significantly prevented the establishment of latent HSV infection in the trigeminal ganglia of mice, but systemic treatment with BVDU did not influence already established latent HSV-1. The chemotherapeutic efficacy of BVDU was comparable to that of acyclovir in the present animal model.
N H Park, and
D Pavan-Langston, and
H M Boisjoly, and
E De Clercq
January 1991,
Intervirology,
N H Park, and
D Pavan-Langston, and
H M Boisjoly, and
E De Clercq
April 1995,
Acta virologica,
N H Park, and
D Pavan-Langston, and
H M Boisjoly, and
E De Clercq
September 1982,
Antimicrobial agents and chemotherapy,
N H Park, and
D Pavan-Langston, and
H M Boisjoly, and
E De Clercq
January 1982,
The Journal of infectious diseases,
N H Park, and
D Pavan-Langston, and
H M Boisjoly, and
E De Clercq
May 1984,
Antimicrobial agents and chemotherapy,
N H Park, and
D Pavan-Langston, and
H M Boisjoly, and
E De Clercq
March 1986,
Antiviral research,
N H Park, and
D Pavan-Langston, and
H M Boisjoly, and
E De Clercq
June 1985,
Antiviral research,
N H Park, and
D Pavan-Langston, and
H M Boisjoly, and
E De Clercq
August 1984,
Antimicrobial agents and chemotherapy,
N H Park, and
D Pavan-Langston, and
H M Boisjoly, and
E De Clercq
April 1987,
Molecular pharmacology,
N H Park, and
D Pavan-Langston, and
H M Boisjoly, and
E De Clercq
March 1985,
Journal of clinical microbiology,
